Is SRRK or LKFT more profitable?

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -160.19% -87.18% Lakefront Biotherapeutics American Depositary Shares N/A N/A N/A

Lakefront Biotherapeutics American Depositary Shares (LKFT) Competitors

$27.71 -0.78 (-2.74%)

As of 02:20 PM Eastern

Compare

LKFT vs. RYTM, SRRK, CGON, MIRM, and TVTX

Should you buy Lakefront Biotherapeutics American Depositary Shares stock or one of its competitors? Lakefront Biotherapeutics American Depositary Shares's main competitors and comparable companies include Rhythm Pharmaceuticals (RYTM), Scholar Rock (SRRK), CG Oncology (CGON), Mirum Pharmaceuticals (MIRM), and Travere Therapeutics (TVTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Lakefront Biotherapeutics American Depositary Shares compare to Rhythm Pharmaceuticals?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.97, indicating that its share price is 97% more volatile than the broader market.

In the previous week, Rhythm Pharmaceuticals had 6 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 8 mentions for Rhythm Pharmaceuticals and 2 mentions for Lakefront Biotherapeutics American Depositary Shares. Rhythm Pharmaceuticals' average media sentiment score of 1.30 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.77 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Lakefront Biotherapeutics American Depositary Shares presently has a consensus target price of $30.67, suggesting a potential upside of 10.55%. Rhythm Pharmaceuticals has a consensus target price of $141.12, suggesting a potential upside of 37.54%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Rhythm Pharmaceuticals is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	0 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.74

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Lakefront Biotherapeutics American Depositary Shares, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.45	$363.05M	-$1.41	N/A
Rhythm Pharmaceuticals	$189.76M	37.05	-$196.54M	-$3.11	N/A

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -85.59%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%

Summary

Lakefront Biotherapeutics American Depositary Shares beats Rhythm Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

In the previous week, Scholar Rock had 3 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 5 mentions for Scholar Rock and 2 mentions for Lakefront Biotherapeutics American Depositary Shares. Scholar Rock's average media sentiment score of 1.10 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.77 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.1% of Scholar Rock shares are owned by institutional investors. Comparatively, 32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. 10.3% of Scholar Rock shares are owned by company insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Scholar Rock has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market.

Scholar Rock presently has a consensus price target of $58.77, suggesting a potential upside of 2.88%. Lakefront Biotherapeutics American Depositary Shares has a consensus price target of $30.67, suggesting a potential upside of 10.55%. Given Lakefront Biotherapeutics American Depositary Shares' higher probable upside, analysts plainly believe Lakefront Biotherapeutics American Depositary Shares is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	4 Strong Buy rating(s)	3.06
Lakefront Biotherapeutics American Depositary Shares	0 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-160.19%	-87.18%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Scholar Rock. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.45	$363.05M	-$1.41	N/A

Summary

Scholar Rock beats Lakefront Biotherapeutics American Depositary Shares on 9 of the 15 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to CG Oncology's net margin of -3,602.68%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	-3,602.68%	-25.20%	-23.98%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

In the previous week, CG Oncology had 5 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 7 mentions for CG Oncology and 2 mentions for Lakefront Biotherapeutics American Depositary Shares. CG Oncology's average media sentiment score of 1.43 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.77 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Lakefront Biotherapeutics American Depositary Shares, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,618.56	-$160.99M	-$2.69	N/A
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.45	$363.05M	-$1.41	N/A

26.6% of CG Oncology shares are held by institutional investors. Comparatively, 32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. 4.8% of CG Oncology shares are held by company insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

CG Oncology currently has a consensus price target of $87.78, suggesting a potential upside of 18.99%. Lakefront Biotherapeutics American Depositary Shares has a consensus price target of $30.67, suggesting a potential upside of 10.55%. Given CG Oncology's stronger consensus rating and higher probable upside, equities analysts plainly believe CG Oncology is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Lakefront Biotherapeutics American Depositary Shares	0 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

CG Oncology has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

Summary

Lakefront Biotherapeutics American Depositary Shares beats CG Oncology on 10 of the 17 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to Mirum Pharmaceuticals?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market.

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -139.18%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%

Lakefront Biotherapeutics American Depositary Shares currently has a consensus target price of $30.67, suggesting a potential upside of 10.55%. Mirum Pharmaceuticals has a consensus target price of $137.31, suggesting a potential upside of 36.34%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	0 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Mirum Pharmaceuticals. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.45	$363.05M	-$1.41	N/A
Mirum Pharmaceuticals	$521.31M	12.54	-$23.36M	-$14.55	N/A

In the previous week, Mirum Pharmaceuticals had 11 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 13 mentions for Mirum Pharmaceuticals and 2 mentions for Lakefront Biotherapeutics American Depositary Shares. Mirum Pharmaceuticals' average media sentiment score of 0.92 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.77 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Mirum Pharmaceuticals beats Lakefront Biotherapeutics American Depositary Shares on 9 of the 16 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to Travere Therapeutics?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Travere Therapeutics (NASDAQ:TVTX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by insiders. Comparatively, 4.4% of Travere Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Travere Therapeutics had 2 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 4 mentions for Travere Therapeutics and 2 mentions for Lakefront Biotherapeutics American Depositary Shares. Travere Therapeutics' average media sentiment score of 1.42 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.77 indicating that Travere Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Travere Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Lakefront Biotherapeutics American Depositary Shares, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.45	$363.05M	-$1.41	N/A
Travere Therapeutics	$490.73M	12.63	-$25.55M	-$0.46	N/A

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Travere Therapeutics' net margin of -7.35%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Travere Therapeutics	-7.35%	-55.15%	-6.88%

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

Lakefront Biotherapeutics American Depositary Shares currently has a consensus price target of $30.67, suggesting a potential upside of 10.55%. Travere Therapeutics has a consensus price target of $61.67, suggesting a potential downside of 6.24%. Given Lakefront Biotherapeutics American Depositary Shares' higher possible upside, equities analysts clearly believe Lakefront Biotherapeutics American Depositary Shares is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	0 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Summary

Lakefront Biotherapeutics American Depositary Shares beats Travere Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Lakefront Biotherapeutics American Depositary Shares News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LKFT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LKFT vs. The Competition

Export

Metric	Lakefront Biotherapeutics American Depositary Shares	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.83B	$3.92B	$7.07B	$12.90B
Dividend Yield	N/A	3.60%	2.54%	9.14%
P/E Ratio	-19.67	12.58	271.49	25.46
Price / Sales	1.45	1,369.00	625.75	92.84
Price / Cash	39.24	45.00	28.92	35.62
Price / Book	0.58	16.21	10.98	6.44
Net Income	$363.05M	-$22.81M	$3.48B	$358.18M
7 Day Performance	-2.84%	1.05%	0.38%	1.04%
1 Month Performance	2.74%	5.62%	3.44%	-0.44%
1 Year Performance	-17.32%	48.73%	23.27%	13.84%

Lakefront Biotherapeutics American Depositary Shares Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LKFT Lakefront Biotherapeutics American Depositary Shares	1.2928 of 5 stars	$27.71 -2.7%	$30.67 +10.7%	-14.6%	$1.83B	$1.26B	N/A	1,310
RYTM Rhythm Pharmaceuticals	2.8573 of 5 stars	$105.22 -0.9%	$141.12 +34.1%	+0.6%	$7.21B	$189.76M	N/A	140	Positive News
SRRK Scholar Rock	1.4906 of 5 stars	$55.84 -1.7%	$58.77 +5.3%	+76.2%	$6.80B	N/A	N/A	140	Positive News Analyst Forecast
CGON CG Oncology	3.5856 of 5 stars	$75.49 +0.4%	$83.18 +10.2%	+125.8%	$6.69B	$4.04M	N/A	61	Positive News
MIRM Mirum Pharmaceuticals	3.6314 of 5 stars	$98.65 +0.6%	$137.31 +39.2%	+32.7%	$6.41B	$521.31M	N/A	140	Positive News Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LKFT) was last updated on 9/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lakefront Biotherapeutics American Depositary Shares (LKFT) Competitors

LKFT vs. RYTM, SRRK, CGON, MIRM, and TVTX

How does Lakefront Biotherapeutics American Depositary Shares compare to Rhythm Pharmaceuticals?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Scholar Rock?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to CG Oncology?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Mirum Pharmaceuticals?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Travere Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LKFT vs. The Competition

Lakefront Biotherapeutics American Depositary Shares Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lakefront Biotherapeutics American Depositary Shares (LKFT) Competitors

LKFT vs. RYTM, SRRK, CGON, MIRM, and TVTX

How does Lakefront Biotherapeutics American Depositary Shares compare to Rhythm Pharmaceuticals?

Which has more risk & volatility, LKFT or RYTM?

Does the media refer more to LKFT or RYTM?

Do insiders and institutionals hold more shares of LKFT or RYTM?

Do analysts recommend LKFT or RYTM?

Which has higher valuation and earnings, LKFT or RYTM?

Is LKFT or RYTM more profitable?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Scholar Rock?

Does the media refer more to SRRK or LKFT?

Do institutionals & insiders hold more shares of SRRK or LKFT?

Which has more volatility & risk, SRRK or LKFT?

Do analysts prefer SRRK or LKFT?

Is SRRK or LKFT more profitable?

Which has stronger earnings and valuation, SRRK or LKFT?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to CG Oncology?

Is CGON or LKFT more profitable?

Does the media favor CGON or LKFT?

Which has better earnings & valuation, CGON or LKFT?

Do insiders & institutionals have more ownership in CGON or LKFT?

Do analysts prefer CGON or LKFT?

Which has more volatility and risk, CGON or LKFT?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Mirum Pharmaceuticals?

Which has more volatility & risk, LKFT or MIRM?

Do insiders & institutionals have more ownership in LKFT or MIRM?

Is LKFT or MIRM more profitable?

Do analysts rate LKFT or MIRM?

Which has preferable valuation and earnings, LKFT or MIRM?

Does the media refer more to LKFT or MIRM?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Travere Therapeutics?

Do insiders & institutionals hold more shares of LKFT or TVTX?

Does the media prefer LKFT or TVTX?

Which has preferable earnings & valuation, LKFT or TVTX?

Is LKFT or TVTX more profitable?

Which has more risk and volatility, LKFT or TVTX?

Do analysts rate LKFT or TVTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LKFT vs. The Competition

Lakefront Biotherapeutics American Depositary Shares Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools